Accelerate And De-Risk Bioconjugate Drug Development

By Elisabeth Engelsberger, Ph.D., and Raphael Frey, Ph.D.

Bioconjugate therapeutics have undergone significant changes and advancements over time. They have evolved from simple protein-polymers to complex, multifunctional molecules that can be tailored for a variety of applications, including drug delivery, imaging, and diagnostics. In recent years, we have seen novel bioconjugates emerge that consist of alternative protein modalities and non-traditional payloads, such as nucleic acids, peptides, and imaging agents. On top of that, novel conjugation chemistries now enable more controlled and site-specific linkages, driving the development of new and improved bioconjugate drugs.

The Lonza Bioconjugation Toolbox is a uniquely developed concept that offers a variety of conjugation technologies, linkers, and payloads. Based on scientific rationale and our experience, we choose the technology which fits best your drug concept and product requirements.

This article provides more detail on Lonza's toolbox technologies and their key features as well as delving into more detail on Lonza's current technology partners, giving a brief description of their technology and highlighting some key features.